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Abstract: Human immunodeﬁciency virus type 1 (HIV-1) is the
retrovirus responsible for the development of AIDS. Its profound
impact on the immune system leaves the host vulnerable to a wide range
of opportunistic infections not seen in individuals with a competent
immune system. Pulmonary infections dominated the presentations in
the early years of the epidemic, and infectious and noninfectious lung
diseases remain the leading causes of morbidity and mortality in persons
living with HIV despite the development of effective antiretroviral
therapy. In addition to the long known immunosuppression and
infection risks, it is becoming increasingly recognized that HIV
promotes the risk of noninfectious pulmonary diseases through a number
of different mechanisms, including direct tissue toxicity by HIV-related
viral proteins and the secondary effects of coinfections. Diseases of the
airways, lung parenchyma and the pulmonary vasculature, as well as
pulmonary malignancies, are either more frequent in persons living with
HIV or have atypical presentations. As the pulmonary infectious
complications of HIV are generally well known and have been reviewed
extensively, this review will focus on the breadth of noninfectious
pulmonary diseases that occur in HIV-infected individuals as these may
be more difﬁcult to recognize by general medical physicians and
subspecialists caring for this large and uniquely vulnerable population.
Key Indexing Terms: Lung; HIV; Pulmonary hypertension; Lung can-
cer; Interstitial lung disease. [Am J Med Sci 2014;348(6):502–511.]
C hronic HIV infection preys on the immune system andrenders individuals susceptible to a range of opportunistic
infections not seen in the immunocompetent host. A diagnosis
of HIV infection in the mid-1980s resulted in a rapidly fatal
course in most individuals as there were no therapies available to
limit viral replication. However, the advent of highly active
antiretroviral therapy (HAART, now known simply as antire-
troviral therapy or ART) almost 20 years ago transformed HIV
into a chronic disease with a much more optimistic prognosis,
and individuals who are adherent to ART are now living more
than 3 decades with the disease.1 Unfortunately, it remains a
“chronic disease” and not merely a silent infection, and persons
living with HIV still suffer greater morbidities and mortality
than the general population despite the incredible advances
in the ﬁeld. Due to the immunosuppressive nature of the dis-
ease, including its primary (albeit not exclusive) infection and
ultimate depletion of CD4+ T-cell lymphocytes, clinicians natu-
rally focus on infectious etiologies when these patients present to
medical attention. However, while opportunistic infections still
remain a signiﬁcant concern in HIV-infected individuals, an
impressive body of research spanning epidemiologic studies to
cell culture models emphasizes the importance of noninfectious
diseases in this population as well. HIV clearly affects the body
in ways beyond T-cell biology alone. Pulmonary disorders
remain a signiﬁcant source of morbidity and mortality even in
the current era, and the broadening scope of the manifestations of
chronic HIV infection requires treating clinicians to expand their
previous differential diagnoses for respiratory complaints even in
the context of adherence to ART. New therapies for the disease
have in fact brought with them a host of new complications
previously not seen in HIV infection, such as sarcoidosis. In this
article, we review the major noninfectious pulmonary complica-
tions of HIV infection and emphasize the current areas of interest
from both a research and a clinical perspective.
Part 1: HIV-Associated Airway Diseases
Disease of the airways, particularly asthma, emphysema and
bronchiectasis, have all been associated with HIV infection.
Asthma, which is characterized by airway inﬂammation and
reversible airﬂow limitation, can cause signiﬁcant morbidity and
even mortality.2 Epidemiologic data examining the relationship
between HIV infection and asthma have been mixed, with some
studies showing that HIV-infected patients have increased levels of
airway hyperreactivity, a feature common in asthma3 and others
failing to show an association.4 The Veterans Aging Cohort Study
thus far suggests that HIV is not associated with higher rates of
asthma,5 whereas other studies indicate a higher rate than expected.6
In contrast, an association between emphysema and HIV
infection seems clearer, with the ﬁrst evidence of an association
emerging more than 2 decades ago.7 Cohort data, again from
the Veterans Aging Cohort Study, support this association and
suggest that HIV infection confers a statistically signiﬁcant
increase in rates of chronic obstructive pulmonary disease
(COPD; a clinical term encompassing emphysema and chronic
bronchitis). Data from International Classiﬁcation of Diseases-9
(ICD-9) codes entered during hospitalizations and patient self-
reports8 support such an effect as do studies using spirometry to
evaluate cohorts of HIV-infected individuals.9
Bronchiectasis, which is characterized by pathologic
dilation of conducting airways, impaired mucociliary clear-
ance and recurrent infections, has been reported to be
increased in the pediatric HIV population.10 Moreover, several
studies have shown a higher-than-expected rate of bronchiec-
tasis in persons living with HIV.11–13 The association is not
surprising as recurrent and/or severe airway infections are risk
factors for the development of bronchiectasis, and even other-
wise healthy individuals living with HIV have much higher
rates of acute bronchitis and bacterial pneumonia than the
general population.
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Pathogenesis
The etiology of airway disease in HIV-infected individ-
uals is certainly multifactorial, but several speciﬁc mechanisms
merit discussion. Cohort data suggest a possible association
between the development of asthma and bacterial or Pneumo-
cystis jiroveci pneumonia, as well as an elevated sputum eosin-
ophil count in a signiﬁcant number of affected individuals.6 In
addition, certain chemokines, such as RANTES, have been
implicated in both asthma and HIV infection.14,15 Tobacco
use is almost certainly playing a role and it is well known to
affect asthma control, and rates of tobacco use continue to be
high among HIV-infected individuals.16
In persons living with HIV who meet clinical criteria for
COPD, tobacco use is clearly a major factor but this alone does
not explain their increased risk when compared with uninfected
individuals with similar smoking histories. Therefore, other
mechanisms must be contributing to the pathogenesis of earlier
and/or more severe airway destruction in these individuals. One
cohort study examining the relationship between obstructive
lung disease and HIV infection found a signiﬁcant increase in
viral load in those developing COPD17 even though CD4 counts
were similar between the groups with and without COPD.
Experimental models have identiﬁed that HIV-related viral pro-
teins, which are present in relatively high concentrations in the
airway, cause lung epithelial barrier dysfunction and impair
innate immunity as reﬂected by a decreased ability to clear
a bacterial challenge from the lung.18,19 Respiratory muscle
function, which can be clinically relevant in the later stages
of obstructive lung diseases, is also diminished in HIV infec-
tion.20 In addition, coinfections may play a role as studies in
animal models show that Pneumocystis colonization may render
the lung susceptible to the development of emphysema.21,22 In
addition, the overall inﬂammatory milieu within the airways in
HIV-infected individuals may also play a role, with some stud-
ies showing that alveolar macrophages produce enzymes such
as matrix metalloproteases that degrade tissue in areas of
emphysematous lung.23 In parallel, oxidative stress, which
likely contributes to the development of COPD in general,24
is signiﬁcantly increased in the airways of HIV-1 transgenic
animals.18,25 These experimental ﬁndings are consistent with
the long-recognized indices of oxidative stress and glutathione
deﬁciency in persons living with HIV.26
As would be expected, bronchiectasis seems to be
associated with HIV infection in the setting of bacterial pneumonia
and acute bronchitis. However, in at least 1 pediatric case series,
lymphocytic interstitial pneumonitis, also known as lymphocytic
interstitial pneumonia (LIP; which is much more common in HIV-
infected individuals) was associated with the development of
bronchiectasis even in the absence of chronic infections.27 In addi-
tion, analyses of sputum samples from HIV-infected children with
bronchiectasis found high levels of interleukin-8 (IL-8) and immu-
noglobulin E (IgE) and positive cultures for either the bacteria
Haemophilus inﬂuenzae or the virus parainﬂuenza in almost half
of the subjects.28 Although at present one cannot state deﬁnitively
that HIV-related infections are a direct cause of bronchiectasis, the
prevailing view among experts is that bronchiectasis is increased
in HIV-infected individuals as a result of more frequent and/or
more severe airway infections that mediate airway wall damage.
Clinical Aspects
In terms of general pulmonary function, HIV-infected
individuals studied in several cohorts have normal airﬂows at
baseline29,30 but their diffusing capacity of carbon monoxide
seems to be diminished.31 Whether the latter ﬁnding represents
early emphysema or pulmonary vascular disease is unknown. In
some cohorts, airﬂow limitation has been linked speciﬁcally
to the use of antiretroviral medications.32,33 Consistent with
these ﬁndings, abnormal declines in airﬂows as assessed by
spirometry have been documented in both smokers and non-
smokers on ART.34
The presentations of airway diseases are not different in
HIV-infected individuals and include the typical complaints of
dyspnea on exertion, cough and wheezing. In this context, the
clinician caring for these individuals should use the same
diagnostic tests to distinguish asthma, COPD and bronchiecta-
sis as would be used in individuals without HIV. Speciﬁcally, in
addition to a thorough history with a particular emphasis on
tobacco use, routine pulmonary function testing and chest
imaging are usually sufﬁcient to make an accurate diagnosis. As
in the general population, HIV-infected individuals with asthma
may have a normal lung examination during exacerbation-free
periods, and diminished breath sounds and end-expiratory
wheezing can occur in both asthma and emphysema depending
on the severity of the disease. Chronic bronchitis, which is part
of the COPD spectrum, and bronchiectasis are characterized by
bothersome chronic coughing that is typically productive of
signiﬁcant amounts of sputum (particularly in bronchiectasis).
More severe cases of bronchiectasis may present with consti-
tutional symptoms (including low-grade fevers, night sweats
and weight loss) that should prompt a search for atypical
infections including those caused by Mycobacterium avium
complex and fungi.
Tobacco cessation is an essential cornerstone of pulmo-
nary management in the HIV-infected population due to the
increased risk conferred by tobacco use in the development of
airﬂow-limiting diseases.35,36 Speciﬁc data on the treatment of
these diseases in the HIV-infected population are limited, but
case reports suggest caution with the use of inhaled cortico-
steroids and the protease inhibitor ritonavir37,38 as this combi-
nation seems to confer a higher risk for steroid-related
complications.
Part 2: HIV-Related Interstitial Lung Diseases
Certain interstitial lung diseases (ILD) have also been
associated with HIV infection. More importantly, the differen-
tial diagnosis for ILD is altered and reordered by the presence
of HIV and treatment with ART. In the pre-HAART era,
a number of ILDs were described in HIV-infected patients that
were thought to arise from systemic immune dysregulation,
including nonspeciﬁc interstitial pneumonitis (NSIP) and LIP.
In the current ART era and subsequent stabilization of
underlying immune function, other ILDs are being recognized
and described.
Pathogenesis
The various HIV-related ILDs have been tied to
a number of experimental mechanisms, but no clear unifying
etiology has emerged beyond the broad categories of immune
dysregulation and reconstitution as well as some associated
coinfections. LIP, which is seen in several rheumatologic
disorders including Sjögren’s syndrome and rheumatoid arthri-
tis,39 is characterized by an inﬂux of lymphocytes into the
alveolar space. It is thought to represent part of a spectrum
of lymphoid pneumonidites that also includes NSIP and follic-
ular bronchiolitis. An association between HLA-DR5 and
HLA-DR6 in blacks and HLA-DR7 in whites has been found
in HIV-infected individuals presenting with CD8+ lymphocytic
inﬁltrates,40 termed diffuse inﬁltrative lymphocytosis syn-
drome. The pulmonary inﬁltration, in particular, is thought to
be due to recruitment by chemoattractants, redistribution of
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blood to the lungs and a proliferation of CD8+ T cells in situ in
response to viral antigens with local elaboration of inﬂamma-
tory cytokines.41 The presence of HIV and HIV-related pro-
teins in germinal centers, the pulmonary interstitium and
bronchoalveolar lavage ﬂuid of patients with LIP support
a direct causative role for the virus42 in this condition. In con-
trast, other evidence suggests a role for coinfections in the
development of lymphoproliferative pulmonary disease in
HIV, including with Epstein–Barr virus,43 cytomegalovirus44
and human T-lymphotrophic virus 1.45
Since the advent of HAART, both LIP and NSIP seem to
be less common in persons living with HIV, again emphasizing
the importance of immune dysregulation in the development of
both diseases. However, the widespread use of ART has
brought with it the rise of other HIV-related ILDs, likely as
a result of immune reconstitution. Reports of sarcoidosis,
a disorder of unknown etiology that is characterized by
granulomatous inﬂammation and a CD4+ alveolitis, were
almost nonexistent pre-HAART but are now found with some
regularity in the literature.46,47 The most commonly invoked
explanation for the change in epidemiology is the development
of immune reconstitution inﬂammatory syndrome (IRIS) in pa-
tients started on ART. IRIS is thought to result from the over-
exuberant response of a previously dampened immune system
to a host of previously recognized antigens or subclinical in-
fections.48,49 Clinical data suggesting that sarcoidosis most
often occurs when the CD4 count exceeds 200 cells/mL sup-
ports the role of IRIS in its development.50
Other ILDs have been noted in persons living with HIV
in the post-HAART era, including cryptogenic organizing
pneumonia (COP) and hypersensitivity pneumonitis (HP).
COP has been associated with P jiroveci pneumonia51,52 and
is also thought to represent a manifestation of IRIS. Similarly,
HP, which results from a disordered CD8+ inﬂammatory
response to an extrinsic allergen, was rarely if ever seen in
the pre-HAART era. With the advent of HAART, it has been
described in HIV-infected individuals exposed to a number of
agents, notably efavirenz53 and bleomycin.54
Clinical Presentation
Most of the ILDs described in HIV-infected individuals
present in a similar fashion. Dyspnea and cough, which are
typically subacute in duration, are frequently described along
with low-grade fevers. Individuals presenting with LIP as
a manifestation of underlying diffuse inﬁltrative lymphocytosis
syndrome frequently show other features commonly seen in
Sjögren’s syndrome such as xerostomia (“dry mouth”) and
xerophthalmia (“dry eyes”).55 Presentations of sarcoidosis vary
widely depending on the involved organ systems. All of these
diseases may be accompanied by other systemic symptoms,
such as fatigue and weight loss. On examination, ﬁne inspira-
tory crackles are often present, but their absence does not rule
out the presence of signiﬁcant disease. Physical examination in
sarcoidosis and LIP will again vary depending on the involved
organ systems, but attention should be paid to lymphadenopa-
thy and hepatosplenomegaly.
Laboratory data are often nonspeciﬁc and are not
typically useful in making a discrete diagnosis. For example,
in most cases, there will be an increased alveolar-arterial oxygen
gradient on arterial blood gas analysis. However, the CD4 count
itself may offer some etiologic clues. As discussed above, HP
and sarcoidosis will frequently present after the initiation of
ART and usually only when the CD4 count rebounds above 200
cells/mL. In contrast, COP has been described at variable CD4
levels in the setting of ART initiation. Although in most cases of
ILD there will be evidence of interstitial inﬁltrates on chest
imaging, chest radiographs can be normal, particularly in NSIP,
although NSIP is typically associated with ground glass opaci-
ties and ﬁbrosis (Figure 1A). The presence of bilateral hilar
adenopathy in association with parenchymal abnormalities is
highly suggestive of sarcoidosis. HP often appears with bilateral
nodules, whereas COP usually presents as a focal consolidation.
On computerized tomography (CT) scans, the majority of indi-
viduals will have ground glass opacities, with the exception of
those with COP. Honeycombing, a radiographic sign that re-
ﬂects relatively severe ﬁbrosis, is usually only seen in advanced
cases of sarcoidosis and HP. Honeycombing can also be seen in
LIP, which is also associated with so-called “tree-in-bud”
FIGURE 1. (A) Characteristic chest computerized tomographic
findings of nonspecific interstitial pneumonitis are seen in this
image, including ground glass opacities, bronchiectasis and
fibrosis (arrow). Image provided by courtesy of Dr. Travis Henry.
(B) Histopathological features of nonspecific interstitial pneu-
monitis are evident in this hematoxylin and eosin stain of an open
lung biopsy section, including interstitial infiltration of lympho-
cytes, macrophages and plasma cells. Image provided by cour-
tesy of Dr. Anthony Gal.
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opacities and peribronchial cufﬁng (Figure 2A). The bronchoal-
veolar lavage ﬂuid in many of these diseases typically reveals
a lymphocytic alveolitis, and ﬂow cytometric analyses to deter-
mine if there is a CD4+ or a CD8+ predominance can help
narrow the differential diagnosis. In contrast, a signiﬁcant per-
centage of eosinophils in the lavage ﬂuid (usually .10%) may
be seen in drug-induced HP. As some infections may mimic
ILDs, it is incumbent on the clinician to rule out occult infec-
tion. In the relatively unique context of IRIS, the exuberant
inﬂammatory response in the lung may in fact be in the presence
of a known pathogen such as M avium complex. In most cases
of ILD, pulmonary function tests reveal a decrease in the dif-
fusing capacity for carbon monoxide and a restrictive lung
defect with relatively preserved airﬂows. However, airﬂow lim-
itation may be present in sarcoidosis, HP and LIP. Pathologic
specimens will usually demonstrate granulomas in patients with
HP and sarcoidosis, whereas diseases on the spectrum of lym-
phocytic proliferation (NSIP, LIP, etc.) will show varying de-
grees of lymphocyte inﬁltration in the interstitium and within
the alveolar spaces (Figures 1B and 2B). In contrast, COP will
appear as an organizing pneumonia on histologic examination.
Treatment
As discussed above, NSIP and LIP are manifestations of
immune dysregulation and are seen much less frequently in the
current ART era. HIV-related NSIP is frequently self-limiting
and rarely requires speciﬁc therapy. Stability or resolution of
LIP has been described with corticosteroids, but there is as yet
no standardized dosing or duration schedule given the infre-
quency of the disease. HP will frequently resolve completely
after discontinuation of antigen exposure, although severe cases
may require treatment with corticosteroids as well. Sarcoidosis
rarely requires speciﬁc treatment either because most cases will
spontaneously remit. Steroids can be considered in patients with
an acute presentation but should be tapered promptly to avoid
the effects of further immune compromise in these already
vulnerable individuals.
Part 3: HIV-Related Pulmonary Hypertension
Pulmonary hypertension (PH), deﬁned by a mean pul-
monary arterial pressure $25 mm Hg at rest when measured
directly by right heart catheterization (RHC), is classiﬁed into 5
different groups on the basis of underlying etiology and comor-
bid conditions. Group 1 PH, also known as pulmonary arterial
hypertension (PAH), includes idiopathic disease, portopulmo-
nary hypertension (ie, PH associated with cirrhosis and portal
hypertension), pulmonary veno-occlusive disease and human
immunodeﬁciency virus–related pulmonary arterial hyperten-
sion (HRPAH). Although the mechanisms of the association
with HIV are not fully understood, PAH is now recognized
as a complication of living with HIV. It was ﬁrst described in
1987 in a 40-year-old man with a plexiform pulmonary vascul-
opathy.56 Since then, several studies have attempted to ascertain
the true prevalence of the disease. As is true for many condi-
tions associated with PH, the exact prevalence of PAH in pa-
tients with HIV is widely variable depending on the modality
used to screen the population, speciﬁcally transthoracic echo-
cardiography (TTE) versus RHC. Using TTE, 1 study reported
a ﬁgure of 0.5% in 1991 based on a cohort of 1,200 subjects.57
Another cohort of more than 7,000 individuals living with HIV
in France used an algorithm that screened patients with unex-
plained dyspnea using TTE and proceeded to RHC if the tri-
cuspid valve regurgitant velocity was more than 2.5 m/s
(reﬂecting possible PH to a degree that produces tricuspid valve
regurgitation). They reported a prevalence of 0.46%, roughly
similar to the ﬁgure reported by the prior cohort.58 A cross-
sectional study found a higher prevalence of HRPAH in women
than men (ratio of 1.4:1) when TTE was used to estimate pul-
monary artery systolic pressures.59 Two more recent studies,
both performed in Spain, found higher rates of HRPAH than
have been previously reported: one found a prevalence of 2.6%
in an asymptomatic cohort of HIV-infected individuals60 and
the other found a rate of 10%.61 Of note, both studies used TTE
to screen their populations, and as reported by others, TTE
overestimates the presence of true PH conﬁrmed by direct cath-
eter measurements and does not provide an accurate assessment
of pulmonary vascular pressures.62 However, even if the inci-
dence of signiﬁcant PH in persons living with HIV is assumed
FIGURE 2. (A) Chest computerized tomographic findings in
lymphocytic interstitial pneumonitis, also known as lymphocytic
interstitial pneumonitis (LIP) are evident in this image, including
so-called “tree-in-bud” opacities representing lymphocytic
aggregation (arrow) and peribronchial cuffing. Image provided
by courtesy of Dr. Travis Henry. (B) Histopathologically, LIP often
appears as lymphocytic interstitial infiltration as seen in this
hematoxylin and eosin–stained section from an open lung
biopsy. Image provided by courtesy of Dr. Anthony Gal.
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to be approximately 0.5%, this represents a relative risk of
almost a 1,000-fold compared with the general population.
As is the case with many diseases associated with PAH,
survival in HRPAH is worse than in HIV alone. Data from
a Swiss cohort demonstrated a survival rate of 21% at 3 years,
which was signiﬁcantly worse than the prognosis for those
individuals living with HIV who did not have PH.63 More
recent data from a French cohort showed a survival rate of
72% at 3 years, with cardiac function and CD4 counts both
independently predictive of mortality.64
Pathogenesis
A number of mechanisms have been elucidated in the
pathogenesis of HRPAH, but a conclusive picture has yet to
emerge. Inﬂammation, genetics, intravenous drug use, coinfec-
tions and viral proteins themselves have all been implicated.
The HIV-related protein gp120, which circulates in infected
individuals and is the protein detected in screening tests for HIV
infection, has been shown to target pulmonary endothelial cells
and increase secretion of endothelin-1, a potent vasoconstric-
tor.65 Another HIV-related protein, negative factor (Nef), has
been shown to infect endothelial cells in both humans and
animals with HRPAH.66 In addition, bone morphogenic protein
receptor 2 (BMPR-2), which has been implicated in cases of
familial PAH not associated with HIV infection, is suppressed
by the HIV transcriptional transactivator protein (Tat).67,68 Fur-
thermore, the combination of viral proteins and hypoxia has
been shown to synergistically increase the pulmonary artery
pressures in a transgenic animal model.69 Hypoxia inducible
factor 1a (HIF1a) seems to mediate the response to the viral
proteins gp120 and Tat.70 Coinfection with human herpes virus
8 (HHV8) may also play a role as the virus has been found in
plexiform lesions of patients with PAH,71 albeit not consistently
in patients with HRPAH.72–74 Chronic inﬂammation has also
been implicated, with rising levels of inﬂammatory markers
associated with increasing pulmonary artery systolic pressures
and tricuspid regurgitant velocities.75 In addition, drug use has
been shown to potentiate the development of HRPAH in labo-
ratory models.76
Clinical Presentation
As discussed above, the prevalence of elevated pulmo-
nary vascular pressures seems to be increased even in
asymptomatic HIV-infected individuals. However, to date,
there are no speciﬁc clinical guidelines on the screening of
patients with HIV for PH, and this is likely due to the relatively
low overall prevalence of the disease. Individuals with HRPAH
often come to clinical attention when they complain of
nonspeciﬁc symptoms, including progressive dyspnea, chest
pain and syncope, particularly as the disease progresses.77 Char-
acteristic ﬁndings on physical examination include a loud pul-
monic component of the second heart sound, a right ventricular
heave, a murmur of tricuspid regurgitation, peripheral edema
and ascites. Chest radiographs often reveal cardiomegaly and
enlargement of the pulmonary arteries, whereas electrocardio-
graphic evaluation will frequently show right atrial and ventric-
ular enlargement with right axis deviation. TTE ﬁndings are
consistent with those of the electrocardiogram and typically
show pathologic enlargement of the right ventricle and right
atrium and an increase in tricuspid regurgitation. However, as
previously discussed, the estimated pulmonary pressures from
the TTE can overestimate the true pressures in both HIV-
infected and uninfected individuals.62,78 Therefore, when the
clinical presentation and TTE ﬁndings are strongly suggestive
of signiﬁcant PH, most experts recommend RHC and direct
measurement of pulmonary arterial pressures to conﬁrm the
diagnosis of HRPAH. Histologic examination is not necessary
to conﬁrm the diagnosis, but when performed typically reveals
the plexiform vasculopathy characteristic of PAH (Figure 3).
Treatment
Treatment for HRPAH is mainly derived from studies on
PAH in general because few rigorous studies on the treatment
of HRPAH have been performed. The speciﬁc beneﬁt of ART
to decrease the levels of circulating HIV-related proteins is
unclear in this setting; a small clinical study showed no
hemodynamic beneﬁt,64 whereas there is experimental evidence
in animal models that protease inhibitors decrease PH79 and at
least 1 cohort study suggested that ART improved mortality in
HRPAH.80 However, as current guidelines recommend ART for
all HIV-infected individuals regardless of CD4 count or viral
load, its speciﬁc role in the treatment of HRPAH may be moot.
As a cautionary note, ART may interact with other speciﬁc
PAH therapies and therefore the management of this complica-
tion can be particularly challenging.
Other therapies for the treatment of HRPAH include
supplemental oxygen as hypoxemia is well known to exacerbate
pulmonary vasoconstriction. Diuretic therapy is also used to
mitigate the sodium retention caused by the right heart failure
and is titrated to maintain right-sided ﬁlling pressures as near to
normal as possible. Anticoagulation with warfarin is also
recommended for all patients with PAH, with a target Interna-
tional Normalized Ratio (INR) of 1.5 to 2.5, as pulmonary
arterial thrombosis in situ hastens the progression of the pulmo-
nary arteriopathy. Calcium channel blockade can be considered
in patients with a favorable response to vasoreactivity testing.
Phosphodiesterase inhibitors, such as sildenaﬁl, have been used
in PAH with good results, but interactions with ART have lim-
ited their use in HRPAH81 and therefore this combination
FIGURE 3. Hematoxylin and eosin–stained section from an open
lung biopsy in a patient with HIV shows the classic pathologic
feature of pulmonary arterial hypertension; namely, the plexi-
form lesions that occlude blood flow within remodeled pulmo-
nary arteries (arrow points to a typical plexiform lesion). Image
provided by courtesy of Dr. Anthony Gal.
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requires careful monitoring.82 In parallel, small studies examin-
ing the efﬁcacy of bosentan, an endothelin receptor antagonist,
suggest positive effects on several clinical parameters of
HRPAH.83,84 Other endothelin receptor antagonists have not
been studied speciﬁcally in HRPAH, but they have shown efﬁ-
cacy in larger studies of PAH that included patients with
HRPAH.85 In addition, prostacyclin analogs such as epoproste-
nol, which are commonly used in severe PAH, have not been
rigorously studied in HRPAH but seem to be effective based on
the limited available data.86 Overall, there is a relative paucity of
rigorous clinical trials to guide recommendations for treatment in
HRPAH. However, a systematic review of HRPAH suggested
a signiﬁcant beneﬁt to speciﬁc PAH therapy,87 and future studies
will likely reﬁne the therapeutic strategies for this relatively
uncommon but devastating complication of HIV.
Part 4: HIV-Related Pulmonary Malignancies
Broadly speaking, lung malignancies in HIV-infected
patients can be divided into AIDS-deﬁning malignancies
(ADM) and non–AIDS-deﬁning malignancies (NADM). As a cat-
egory, ADM includes Kaposi’s sarcoma (KS) and non-Hodgkin’s
lymphoma (NHL). NADM refers to other primary lung cancers
that have an increased incidence in HIV-infected individuals com-
pared with uninfected individuals but do not deﬁne a transition
from HIV infection to AIDS. The relative increased risk for lung
malignancy conferred by HIV infection has been difﬁcult to quan-
tify, given the high prevalence of tobacco use in this population
that confounds epidemiologic assessments.88,89 Several studies
have shown an increased risk of lung malignancy in the HIV-
infected population,90,91 with many experts now believing HIV to
be an independent risk factor. This risk is likely to be more clearly
validated as the population with HIV lives longer. In contrast,
since the advent of HAART, the ADMs have decreased signiﬁ-
cantly in incidence. This almost certainly reﬂects the role of
immunosuppression and coinfections in their development.
Pathogenesis
The 2 major ADMs seem to be related to both immuno-
suppression and coinfections. The incidence of KS, which is
caused by coinfection with HHV8, is associated with the degree
of immunosuppression and therefore is now far less common in
the ART era.92 It has also been associated with IRIS in a pre-
sentation known as a KS ﬂare, presumably reﬂecting previous
infection with HHV8.93–95 KS behaves like an angioproliferative
tumor that grows in response to a range of cytokines and growth
factors, including IL-1, IL-6, tumor necrosis factor-a and vascu-
lar endothelial growth factor.96 HIV-related viral proteins, such as
Tat, can also promote KS growth,97 and HHV8 likely further
potentiates this growth by an anti-apoptotic mechanism.98
NHL has several different manifestations in HIV-
infected individuals, including Burkitt’s lymphoma and diffuse
large B-cell lymphoma. Epstein–Barr virus is frequently asso-
ciated with NHL in HIV infection, as is the degree of immu-
nosuppression.99 Burkitt’s lymphoma involves translocation of
the c-Myc gene, a key regulator of cell proliferation. Although
less frequent than in cases of KS, NHL has also been associated
with IRIS,100 again highlighting the importance of coinfection
in its pathogenesis.
HIV-infected individuals develop pulmonary NADM at
higher frequencies than that of the general population101 even after
the advent of HAART.102 In recent studies, lung cancer continues
to be the most common NADM,103 and this risk seems to be tied
to the level of immunosuppression104 although tobacco use is
a signiﬁcant confounder. Some have speculated that previous in-
fections and chronic inﬂammation may also play a role in confer-
ring an increased risk of lung cancer in individuals with HIV,105
although the molecular mechanisms remain to be elucidated.
Clinical Presentation
As discussed above, pulmonary KS typically presents in
HIV-infected individuals who have relatively low peripheral
CD4 counts.106 It is most often associated with cough, dyspnea
and fever; these symptoms do not distinguish it from opportu-
nistic infections. Chest radiographs most often show bronchial
wall thickening and nodules, whereas computed tomography
often shows numerous nodules, tumor masses, bronchial wall
thickening and/or bilateral pleural effusions.107 In the setting of
IRIS, KS ﬂares have similar ﬁndings, including reticular and
reticulonodular opacities, consolidation and effusions.108 CT
scans often reveal ﬂame-shaped inﬁltrates extending outward
from the hila into the lung parenchyma along the bronchovas-
cular bundles (Figure 4A). The appearance of ground glass
opacities can also be seen on CT scan but should trigger a search
for concomitant opportunistic infections. Importantly, although
pulmonary KS is usually associated with clinically apparent
mucocutaneous involvement, a signiﬁcant percentage of pa-
tients with pulmonary KS will not have visible lesions on skin
examination and therefore the clinician must maintain a high
level of suspicion in the appropriate clinical context. At bron-
choscopy, KS lesions characteristically appear as purple or red
macules, often at airway bifurcations,109 but may be missed if
they do not involve the airway directly or are too distal to be
visualized. Histologically, KS is diagnosed by its characteristic
spindle cells and high vascularity (Figure 4B).
Patients with AIDS-related NHL frequently present with
cough, dyspnea and constitutional symptoms.110 Physical exami-
nation often demonstrates tachypnea, crackles, lymphadenopathy
and hepatomegaly. Most have advanced HIV, with low CD4
counts increasing the likelihood of the disease. Elevated sedimen-
tation rates and serum levels of lactate dehydogenase levels are
also commonly seen. Chest radiography most often reveals con-
solidation, nodules, reticular inﬁltrates or masses. Pleural effu-
sions can also be seen but less commonly so. On computed
tomography, a cardinal feature is intrathoracic lymphadenopathy.
The diagnosis can be made by transbronchial biopsy and/or endo-
bronchial ultrasound-guided sampling of mediastinal lymph nodes
or by pleural ﬂuid cytology when effusions are large enough to
sample. Surgical lung biopsy has a high diagnostic yield and may
be necessary if other less invasive studies are nondiagnostic, but it
is obviously associated with greater morbidity.
NADMs of the lungs present similarly in HIV-infected
and uninfected individuals, although those with HIV tend to be
younger, with a mean age at diagnosis of approximately 48
years as compared with approximately 60 years in the non–
HIV-infected population,101 although at least 1 study suggests
that the age difference may not be so large between the 2
populations.111 Most studies evaluating NADMs in the lung
have found adenocarcinoma to be the most common cancer
type.112 Unfortunately, HIV-infected individuals tend to present
with more advanced disease,113 although their mortality seems
no higher than the uninfected population if staging is taken into
account. Interestingly, most individuals have a CD4 count
greater than 200 cells/mL at the time of diagnosis.
Treatment
KS is primarily treated with ART, which has been shown
to cause regression of KS lesions. As noted above, however, KS
ﬂares have been described in the setting of ART initiation and
merit particular attention. In patients who do not respond to
ART, chemotherapy and radiotherapy have been used with
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good success, provided the treatments can be tolerated.114–116
However, KS remains a serious complication and the presence
of pulmonary KS signiﬁcantly increases mortality.92
NHL in the HIV-infected patient is usually treated with
chemotherapy. As discussed previously, ART plays an essential
role in preventing the development of NHL. For relatively
refractory cases, high-dose chemotherapy and autologous stem
cell transplantation have also been used.117
For prevention of NADMs, strong emphasis should be
paid to the importance of smoking cessation. For those HIV-
infected individuals identiﬁed with lung cancer who are not on
ART, many clinicians favor initiating ART before starting
chemotherapy in an effort to enhance their overall functional
status. Special care must be taken to avoid interactions between
chemotherapeutic agents and ART.118 However, there are at
present no speciﬁc guidelines for the treatment of HIV-
infected individuals with pulmonary NADMs and no speciﬁc
recommendations regarding the screening of these individuals
for pulmonary malignancy.
SUMMARY
Clinicians caring for individuals living with HIV must be
aware of the wide range of noninfectious pulmonary diseases
that can occur in this unique population, particularly as the
prognosis has dramatically changed with the advent of effective
ART. Cohort studies indicate that many of these diseases occur
with less frequency in the era of ART, but other diseases that
were virtually nonexistent before the availability of effective
anti-retroviral drugs are now coming to the fore. Laboratory
studies offer insights into the pathogenesis of many of these
processes, but much work remains to be done. From a clinical
standpoint, pulmonary infections remain an important cause of
morbidity and mortality and must be ruled out whenever
possible. However, as people are now living much longer with
HIV and the HIV-infected population ages, noninfectious
pulmonary diseases are becoming more common and even
more important to recognize.
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